CA
NZ
UK
AU
IND
US
Gross margin expanded to 56.8%, up 11 percentage points from the prior quarter, supported by higher pricing, disciplined cost execution, and favorable product mix. Operating income totaled $6.4 billion, representing a 47% operating margin. Non-GAAP diluted earnings per share were $4.78, up 58% sequentially …
Netflix, Inc. enters 2026 following a year in which it met or exceeded its stated financial objectives. Revenue grew 16% in 2025, supported by stronger member acquisition, improved retention, and rapid expansion of its advertising business. Operating profit rose approximately 30%, reflecting both revenue …
Microsoft Corporation enters the 2025–2026 fiscal period with sustained double-digit growth across revenue and earnings, supported primarily by cloud computing and artificial intelligence adoption. Quarterly revenue reached $81.3 billion, increasing 17% in constant currency. Operating income rose 21%, while earnings per share climbed 24% …
Meta Platforms entered 2026 following a year of robust financial expansion. In the fourth quarter of 2025, total revenue reached $58.9 billion, representing a 25% year-over-year increase. Advertising remained the dominant contributor, with Family of Apps ad revenue of $58.1 billion, up 24% (23% …
Xponential Fitness (NYSE:XPOF) plunged 47.08% to $4.26 on February 27, 206, wiping out nearly half itsmarket capitalizationin one session, with volume crossing 1.02 million shares and indicating aggressive institutional selling rather than retail-drivenvolatility.
PAR Technology (NYSE:PAR) dropped 27.03% to $16.39 on February 27, 2026, as investors reacted to concerns over slowing growth in the restaurant SaaS sector.
LiveWire Group (NYSE:LVWR) fell 28.21% to $1.68 on February 27, 2026, signaling deep skepticism toward EV motorcycle demand and scale economics.
Emergent BioSolutions (NYSE:EBS) fell 26.58% to $8.15 as investors responded to ongoing post-pandemicrevenuenormalization. The decline reflects reduced demand for pandemic-related products, highlighting the company’s exposure to fluctuations in vaccine sales and government contracts.
Ginkgo Bioworks (NYSE:DNA) declined 30.48% to $6.75 on February 27, 2026 with heavy selling pressure reflecting a repricing of long-duration biotech growth stocks and volume exceeding 3M shares, indicating broad participation.
At the start of March 2026, that structural relevance was abruptly reaffirmed. West Texas Intermediate (WTI) crude oil surged to around $72.53, sharply higher from the prior close of $67.28. The move represents the most pronounced single-session percentage rise in roughly four years.
Please wait processing your request...